Figures & data
Figure 1. Markov model diagram. Background mortality is included in every state of the model. SVR, sustained virologic response; HCV, hepatitis C virus.
![Figure 1. Markov model diagram. Background mortality is included in every state of the model. SVR, sustained virologic response; HCV, hepatitis C virus.](/cms/asset/4b85c6b4-1e51-445b-b200-9786caa54d97/ijme_a_844159_f0001_b.jpg)
Table 1. Annual transition probabilities (TPs) used within the Markov model.
Table 2. Model inputs.
Table 3. Sustained virological response (SVR) rates inputted into the modelCitation6,Citation21,Citation27.
Table 4. Cost-effectiveness results: base case.
Figure 2. Tornado chart of cost per QALY gained for the T/PR regimen vs PR alone for all treatment-experienced patients. PR, peginterferon/ribavirin; T/PR, telaprevir plus PR; SVR, sustained virologic response; SOC, standard of care; QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio.
![Figure 2. Tornado chart of cost per QALY gained for the T/PR regimen vs PR alone for all treatment-experienced patients. PR, peginterferon/ribavirin; T/PR, telaprevir plus PR; SVR, sustained virologic response; SOC, standard of care; QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio.](/cms/asset/a0eceb79-1051-4f7d-a925-2cf3a6c4c2ec/ijme_a_844159_f0002_b.jpg)
Figure 3. Cost-effectiveness plane: cost per QALY (£/QALY) gained for the T/PR regimen vs PR alone for all treatment-experienced patients. PR, peginterferon/ribavirin; T/PR, telaprevir plus PR; QALY, quality-adjusted life-year.
![Figure 3. Cost-effectiveness plane: cost per QALY (£/QALY) gained for the T/PR regimen vs PR alone for all treatment-experienced patients. PR, peginterferon/ribavirin; T/PR, telaprevir plus PR; QALY, quality-adjusted life-year.](/cms/asset/95d49331-b3d7-460a-befa-80d1b0127de1/ijme_a_844159_f0003_b.jpg)
Figure 4. Cost-effectiveness acceptability curve based on the cost per QALY (£/QALY) gained for the T/PR regimen vs PR alone for all treatment-experienced patients. PR, peginterferon/ribavirin; T/PR, telaprevir plus PR; QALY, quality-adjusted life-year.
![Figure 4. Cost-effectiveness acceptability curve based on the cost per QALY (£/QALY) gained for the T/PR regimen vs PR alone for all treatment-experienced patients. PR, peginterferon/ribavirin; T/PR, telaprevir plus PR; QALY, quality-adjusted life-year.](/cms/asset/05c0853b-0d6f-4711-bade-d50db14b2194/ijme_a_844159_f0004_b.jpg)